FDA Approves First Sensor Pill to Alert Doctors When It’s Ingested

The U.S. Food and Drug Administration (Silver Spring, MD) has approved a pill that includes a sensor that digitally tracks if patients have ingested it.

The United States Federal Drug and Food Administration (FDA) just approved a pill with sensors for the first time. Anti-psychotic drug Abilify MyCite which has a “digital ingestion tracking system” to monitor if the drug was actually ingested has been approved for sale by the administration. In a press release to online media, the FDA wrote: “The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.”

Pill send signal on contact with stomach acid

The pill senses whether the user has ingested it by sending information from an internal sensor to a wearable patch on the patient, this information is then forwarded to either a smartphone app or directly to a monitoring medical professional. The pill is designed to trigger an electrical signal when key ingredients come into contact with stomach acid. The pill contains copper, magnesium, and silicon, which sound alarming, but are actually relatively common “ingredients found in foods.”

Patients who are prescribed the medication are required to sign a consent form. This gives their consent that allows their doctors and up to four other people, including family members, receive the data on their pill taking. Patients have access to a smartphone app that lets them add or block recipients to the data at any time.

Tracking medicine may save lives

There are many reasons why tracking medication is a good idea. Medications related to the management of severe mental health illness such as schizophrenia can be critical to the patient's health but may be forgotten or ignored by a patient. The tracking system can assist not only those that take long-term medications to help themselves keep track of their own medications but can provide peace of mind to their carers, doctors, and families that they are maintaining their medication regime.

Not taking medication when needed or in the manner that is required is called noncompliance and can cost the healthcare system millions of dollars because patients get sicker and need additional treatment or hospitalization. Dr. William Shrank, chief medical officer of the health plan division at the University of Pittsburgh Medical Center explains, saying, “When patients don’t adhere to lifestyle or medications that are prescribed for them, there are really substantive consequences that are bad for the patient and very costly.”

drug for schizophrenia.” Critics aside, the meditation is definitely a breakthrough in a type of biotechnology that we haven’t seen before.

Critics question drug choice

The sensor medication also has its critics. Some say that once the data on which medications you are taking is stored somewhere it could be used by insurance companies to raise premiums. Others question if the medication and its monitoring could become part of parole or family court decisions. Dr. Paul Appelbaum, Columbia University director of law, ethics, and psychiatry wonders if a drug used to treat schizophrenia was the right place for the FDA to start. He asks: “A system that will monitor their behavior and send signals out of their body and notify their doctor? You would think that, whether in psychiatry or general medicine, drugs for almost any other condition would be a better place to start."

Featured Posts
Recent Posts
Archive
Search By Tags

About Pharmanaming.com and GNN

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.

 

With around 240 cooperating naming and branding specialists in 16  countries, from Beijing to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

Pharmaceutical projects are coordinated from the GNN office in Amsterdam by the pharma naming specialists of Globrands.

The www.pharmanaming.com website is dedicated to our expertise and work for the health & pharma industry.

 

Please contact us for more information.

20

offices in 16 countries

240

creatives, strategists & consultants

GNN offices

China                     South Korea

France                   Italy
Germany               Japan

Netherlands          UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai

5000

projects successfully executed

Pages

home                           name to brand

health & pharma        people

regulatory                   test & submit

India                             FDA

work                             blog

clients                          contact

20000

linguistic professionals worldwide

Globrands the name behind the brands

© 2020 by Globrands consultancy group

Herengracht 122, 1015 BT Amsterdam, the Netherlands

call +31206238555 or mail to pharma@globrands.com  

 

  • White LinkedIn Icon